Search Results
May 20, 2026, 08:00 ET Vermont Governor Signs Rare Disease Advisory Council into Law
face compounding barriers to care. The council also includes a geneticist or genetic counselor, a seat that reflects the growing importance of cell and gene therapies: nearly 80% of rare diseases have a genetic origin.The council launches at a pivotal moment. With the recent disbanding of the federal
More news about: National Organization for Rare Disorders (NORD®)
May 20, 2026, 06:57 ET METiS TechBio to Present Late-Breaking Data on Near-Complete Cardiomyocyte Delivery at CRS 2026
for High-Efficiency In Vivo Delivery and Cardiomyocyte Gene Editing."In this study, leveraging its proprietary NanoForge AI nanodelivery platform, METiS TechBio achieved near-complete (~100%) cardiomyocyte transfection and significant gene editing following intravenous administration through AI-driven
More news about: METiS TechBio
May 20, 2026, 06:00 ET Discovery Life Sciences Launches IVDR-Compliant Luminos® Comprehensive with 7-to-10-Day Turnaround for EU Oncology Trials
Germany, May 20, 2026 /PRNewswire/ -- Discovery Life Sciences today launched Luminos® Comprehensive, a 164-gene pan-tumor comprehensive genomic profiling (CGP) panel validated on FFPE tissue as an IVDR-compliant laboratory-developed test and deployed in-house
More news about: Discovery Life Sciences
May 19, 2026, 10:30 ET Jefferson Welcomes Renowned Cancer Researcher and Wistar Institute Leader Dario C. Altieri, MD, to Thomas Jefferson University's Sidney Kimmel Medical College Faculty
understanding how tumor cells survive and proliferate. His studies have been instrumental in understanding survivin, an Inhibitors of Apoptosis (IAP) gene shown to be overproduced in nearly every human cancer, and exploring how it can impact cancer cell survival. He continues to study how cancer cells
More news about: Thomas Jefferson University
May 19, 2026, 10:00 ET EpiCypher and New England Biolabs Expand Strategic Partnership to Advance Epigenomics Research
on a successful track record of collaboration, the partnership will accelerate the creation of innovative technologies that advance understanding of gene regulation, chromatin biology, and disease mechanisms.
More news about: New England Biolabs, Inc.
May 19, 2026, 08:30 ET Greenland Mines Brings Skaergaard to EIT RawMaterials Summit 2026 in Brussels
of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., the Skaergaard
More news about: Greenland Mines Ltd
May 19, 2026, 08:00 ET Rancho BioSciences Launches OmicsHQ™: a Comprehensive, Curated, Multi-Omics Data Platform Built to Accelerate Drug Discovery
harmonization required. Additional data modalities will continue to be added over time.Researchers can visualize UMAP and PCA embeddings, explore gene expression, and evaluate quality control metrics directly within the platform before downloading, making it easier to identify the right dataset before
More news about: Rancho BioSciences
May 19, 2026, 08:00 ET Rancho BioSciences Launches OmicsHQ™: a Comprehensive, Curated, Multi-Omics Data Platform Built to Accelerate Drug Discovery
harmonization required. Additional data modalities will continue to be added over time.Researchers can visualize UMAP and PCA embeddings, explore gene expression, and evaluate quality control metrics directly within the platform before downloading, making it easier to identify the right dataset before
More news about: Rancho BioSciences
May 19, 2026, 06:39 ET Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
2036, expanding at a CAGR of 6.6% during the forecast period. Market growth is being driven by rising biologics production, expanding cell and gene therapy pipelines, increasing adoption of serum-free formulations, and growing demand for reproducible, GMP-grade manufacturing inputs across regulated
More news about: Future Market Insights
May 19, 2026, 06:31 ET Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight
diagnostic techniques and population growth.Role of the SPINK5 Gene in Disease Mechanisms: The pathogenesis basis of Netherton syndrome is well understood, with a definite link to mutations in the SPINK5 gene that have led to the discovery of potential pathways like IL-7 and KLK inhibition.Potential
More news about: DelveInsight Business Research, LLP
May 19, 2026, 02:23 ET Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The Company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
May 19, 2026, 02:20 ET Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The Company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
May 18, 2026, 16:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases,
More news about: REGENXBIO Inc.
May 18, 2026, 14:15 ET M/I HOMES ANNOUNCES ELECTION OF GENE SMITH TO BOARD OF DIRECTORS
M/I Homes."As President of Gene Smith Consulting, LLC, Mr. Smith provides leadership training services, with a particular focus on assisting athletic conference commissioners, athletic directors and coaches in the collegiate environment. Prior to founding Gene Smith Consulting, LLC, Mr. Smith was
More news about: M/I Homes, Inc.
May 18, 2026, 09:05 ET BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
clinicaltrials.biomarin.com.About ENPP1 DeficiencyENPP1 deficiency is a rare and lifelong genetic condition caused by changes in the ENPP1 gene, leading to progressive damage to blood vessels, soft tissues and bones. Infants with this condition are often diagnosed with generalized arterial calcification
More news about: BioMarin Pharmaceutical Inc.
May 18, 2026, 09:00 ET Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
May 18, 2026, 09:00 ET Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
May 18, 2026, 08:46 ET Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
available to more patients and their families."Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in gene expression on chromosome 15 that affects about 10,000 patients in the United States. The disease is characterized by neurological, behavioral, and metabolic
More news about: Neurocrine Biosciences, Inc.
May 18, 2026, 08:00 ET From Breakthrough to Bedside: Children's Mercy Partners with Basepath Health to Expand Delivery of Life-Changing Cell and Gene Therapies
manage chronic symptoms, newer options—such as in vivo and ex vivo gene therapies and CAR-T cell therapy—aim to halt or even reverse disease progression, often with a single treatment."Cell and gene therapies are opening a new era of hope for children, adolescents and young adults
More news about: Children’s Mercy
May 18, 2026, 08:00 ET Roche Highlights Robust Performance of Ellis Bio SuperMethyl™ Kits in New Tech Spotlight Evaluating Five Low‑Input cfDNA Methyl‑Seq Workflows
"Methylation sequencing is becoming an essential tool for understanding gene regulation, cancer biology, and disease progression," said Chuan He, founder of Ellis Bio, University of Chicago Professor, HHMI Investigator and newly
More news about: Ellis Bio Inc
May 18, 2026, 00:18 ET Datar Cancer Genetics erhält wegweisende FDA-Zulassung in den USA für CellDx-Tissue - umfassender Genomprofiling-Test für solide Tumoren
soliden Tumoren.Der Test untersucht 517 krebsassoziierte Gene und liefert Informationen zu somatischen Einzelnukleotidvarianten (SNVs), kleinen Insertionen und Deletionen (InDels), ERBB2-Genamplifikationen sowie Genfusionen der Gene ALK, RET und ROS1. CellDx-Tissue wird zentral im CAP- und CLIA-akkreditierten
More news about: Datar Cancer Genetics
May 18, 2026, 00:05 ET Labbit Introduces Validation Assistant as the Latest Addition to Its Change Management Lifecycle for Regulated Laboratories
workflows.About LabbitLabbit is a modern LIMS platform built for regulated laboratories running complex workflows in molecular diagnostics, cell and gene therapy, and quality control manufacturing. Founded as Semaphore Solutions and recently rebranded as Labbit, the company has staff across North America
More news about: Labbit
May 17, 2026, 12:00 ET Nabsys Announces New OhmX Platform Installations Under Hitachi High-Tech America's RAMP UP Program with Leading Cytogeneticist to Advance Applications in Hematologic Malignancies
biology to deliver high-resolution insight into genome structure. This approach expands what's possible in cytogenetics, molecular genetics, and cell and gene therapy research, while providing comprehensive structural variation analysis to laboratories of all sizes. The company was founded in 2005 and is based
More news about: Nabsys
May 15, 2026, 12:27 ET BioSpace Wins Several Accolades for Biopharma Journalism, Including 2026 Neal and Azbee National Gold Awards
BioSpace team was named as a Neal Award finalist for Best Industry Coverage and Best Commentary for their submissions "Rare Diseases, Cell and Gene Therapy Face Pivotal Moment" and "Weighing In on RFK Jr.'s Attack on Vaccines, mRNA Technology," respectively.The BioSpace team was awarded
More news about: BioSpace
May 15, 2026, 09:59 ET Datar Cancer Genetics reçoit l'autorisation de la FDA des États-Unis pour CellDx-Tissue, un test de profilage génomique complet pour les tumeurs solides utilisant l'ADN et l'ARN
vise à fournir des informations sur les variants somatiques à nucléotide unique (SNV), les petites insertions et délétions (InDels), l'amplification du gène ERBB2 et les fusions de gènes impliquant ALK, RET et ROS1. CellDx-Tissue est un test à site unique réalisé dans le laboratoire
More news about: Datar Cancer Genetics